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Abstract 
 
Here we describe a simple way to create a gold nanoparticle (AuNP) based non-viral delivery 
system to deliver siRNA into prostate cancer cells. Therefore, positively charged 
polyethylenimine (PEI) capped AuNPs were synthesized in water and further conjugated with 
the targeting ligand (folic acid) for folate receptors (AuNPs-PEI-FA). The AuNPs-PEI-FA could 
effectively complex small interfering RNA (siRNA) through electrostatic interaction. Flow 
cytometry displayed that AuNPs-PEI-FA could specifically deliver siRNA into LNCaP cells, a 
prostate cancer cell line overexpressing prostate specific membrane antigen (PSMA), that 
exhibits a hydrolase enzymic activity with a folate substrate. In contrast, internalization of 
siRNA into PC-3 cells, a prostate cancer cell line not expressing PSMA or folate receptors, was 
not achieved using AuNPs-PEI-FA.siRNA. Following endolysosomal escape the AuNPs-PEI-
FA-.siRNA formulation resulted in significant endogenous gene silencing when compared to the 
non-targeted formulation, suggesting the potential of AuNPs-PEI-FA for targeted delivery of 
therapeutic siRNAs in the treatment of prostate cancer. 
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1. Introduction  
 
Prostate cancer is one of the most leading causes of morbidity and mortality in men 
worldwide [1]. Gold nanoparticles (AuNPs) with size/shape dependent optical properties offered 
by the surface plasmon resonance (SPR) are now widely used in biomedical applications, 
including the contrast agents, photothermal agents and radiosensitizers for cancer diagnosis and 
therapy [2, 3]. Furthermore, the affinity of AuNPs to strongly bind biomolecules containing thiol 
and/or amino groups makes them suitable as bioconjugated vehicles for selective drug delivery 
[4]. Small interfering RNA (siRNA) is known to selectively downregulate any gene implicated in 
the pathology of disease [5, 6]. Recent knowledge of molecular genetic data discovered by 
sequencing the whole genome of cancer cells has resulted in significant changes in our 
understanding of the molecular pathogenesis of cancer and has facilitated the identification of a 
number of molecular targets against which RNAi has been developed [7, 8]. Indeed, delivery of 
siRNA using multifunctional nanoparticles (NPs) has been recently investigated to treat solid 
tumours and leukaemia [9-11]. 
In this study cationic bioconjugated AuNPs namely AuNPs-PEI-FA were obtained using 
HAuCl4.3H2O, ascorbic acid, polyethylenimine (PEI) and folic acids [folate, FA; in order to 
target the folate receptor (FR) overexpressed in prostate cancer cells]. Gel retardation showed 
that AuNP-PEI-FA could effectively complex siRNA through electrostatic interaction. Flow 
cytometry displayed that AuNPs-PEI-FA could specifically deliver siRNA into LNCaP cells. 
Consequently, the presence of the FA facilitated cell-specific receptor-mediated uptake and the 
presence of PEI (a polycation with dramatic buffering capacity for ‘proton sponge’ effect) 
induced endolysosomal escape of the siRNA subsequently achieving endogenous gene silencing 
in LNCaP cells. 
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2. Materials 
Prepare all solutions using purified H2O (resistivity ≈ 18.2 MΩ cm) as a solvent for the AuNPs 
synthesis. Clean all glassware used in the synthesis of AuNPs with aqua regia (3 parts of 
concentrated HCl and 1 part of concentrated HNO3), rinse with distilled water, ethanol and 
acetone, and dry in oven before use. Freshly prepared solutions were used (unless specified a 
stock solution). All siRNA solutions were prepared in RNase-free water following Sigma-
Aldrich recommendations.  
2.1 Nanoparticles synthesis and bioconjugation with folic acid 
1. 1 mM Gold(III) chloride trihydrate (HAuCl4.3H2O) ≥99.9% metal basis aqueous 
solution. 
2. 100 mM L-ascorbic acid BioXtra, ≥99.0%, crystalline aqueous solution. 
3. 2.3 mM PEI 2KD, average Mn ~1,800 by GPC, average Mw ~2,000 by LS aqueous 
solution stock at 4 °C. 
4. Glass round flasks. 
5. Magnetic stirrer. 
6.  Sonicator. 
7. Folic Acid BioReagent, suitable for cell culture, suitable for insect cell culture, suitable 
for plant cell culture, ≥97%. 
8. Dimethyl Sulfoxide (DMSO) Anhydrous ≥99.9%. 
9. Trimethylamine ≥99.5%. 
10. N-hydroxysuccinimide (NHS) 98%. 
11. N,N'-Dicyclohexylcarbodiimide (DCC) for synthesis.  
12. Whatman filter papers. 
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13. Schlenk line connected to Argon gas flow to operate under inert atmosphere. 
14. Microbalance.  
15. Centrifugator. 
2.2 Preparation of AuNP.siRNA complexes 
1. AuNPs-PEI and AuNPs-PEI-FA were concentrated to 500 µg mL-1 by centrifugation 
(5000 rpm, 1677 × g for 15 min at RT).  
2. Negative Control siRNA; sense sequence 5′-UUC UCC GAA CGU GUC ACG U-3′; 
desalting purification. 
3. Fluorescein amidite (FAM)-labeled siRNA; sense sequence 5′-UUC UCC GAA CGU 
GUC ACG U-3′, modified by 6-FAM on 5′ of sense sequence; desalting purification. 
4. RelA siRNA; sense sequence 5′-CCA UCA ACU AUG AUG AGU U-3′; desalting 
purification. 
5. Agarose (low gelling temperature, for molecular biology). 
6. Tris/Borate/EDTA (TBE) buffer (BioReagent, suitable for electrophoresis, 10x 
concentrate). 
7. SafeView.  
2.3 Cell culture 
1. RPMI-1640 medium for LNCaP cells (with sodium bicarbonate, liquid, without L-
glutamine, sterile-filtered, suitable for cell culture).  
2. RPMI-1640 medium for PC-3 cells (with L-glutamine and sodium bicarbonate, liquid, 
sterile-filtered, suitable for cell culture).  
3. LNCaP cells, a human prostate cancer cell line PC-3 cells, a human prostate cancer cell 
line.  
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4. 12- and 24-well cell culture plates.  
5. Cell incubator.  
2.4 Fluorescence activated cell sorting, confocal microscopy and in vitro gene knockdown 
1. Polystyrene Round-Bottom Tubes.  
2. 6-well culture plates with glass bottom.  
3. LysoTracker® Deep Red.  
4. GenElute™ Mammalian Total RNA Miniprep Kit.  
5. High-Capacity cDNA Reverse Transcription Kits.  
6. Primers for RelA and GAPDH.  
2.5 Characterization equipments 
1. UV-visible Spectroscopy: CARY UV−visible spectrophotometer with a Xenon lamp 
(190−900 nm range, 0.5 nm resolution) was used to carry out Optical absorption spectra. 
2. Scanning Electron Microscopy (SEM): FEI 630NanoSEM equipped with an Oxford INCA 
energy dispersive X-ray (EDX) detector operating at 5 kV was used to image the AuNPs-PEI 
deposited from solution onto a Si wafer and air-dried prior to analysis. 
3. Dynamic Light Scattering (DLS) and Zeta Potential Measurements: Malvern Zetasizer Nano 
ZS was used to determine the size and charge distributions via dynamic light scattering 
(DLS) and electrophoretic mobility measurements respectively.  
4. Confocal Microscopy: Olympus FV 1000 microscope was used and images were acquired and 
analysed using Olympus FV10-ASW software. 
5. Real-time quantitative PCR (qPCR): Gene expression was assessed by real-time quantitative 
PCR (qPCR) using the Applied Biosystems Real Time PCR System (model 7300). 
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3. Methods  
3.1 Synthesis of folic acid-conjugated gold nanoparticles 
3.1.1 Synthesis of PEI capped gold nanoparticles (AuNPs-PEI) 
1. Add 1.42 mL of 2.3 mM PEI to 32.6 mL of 1 mM HAuCl4.3H2O solution with stirring at 
RT; the colour of the solution was changed from pale yellow to deep orange. 
2. Add to the above solution (after about 1 minute) 0.5 mL of a freshly prepared 100 mM L-
ascorbic acid aqueous solution, the colour change immediately (~ 5 s) to red brownish 
(see Note 1).  
3. Keep the solution stirring gently overnight at RT achieving AuNP-PEI (see Note 2) as 
shown by UV-visible spectroscopy and SEM shown in Fig. 1 (see Note  3). 
3.1.2 Synthesis of Folic acid activated ester (folic acid-NHS) 
1. Dissolve 0.25 g (5.663 × 10-4 mol) of folic acid in 10 mL of dry DMSO.  
2. Add to the above solution 0.125 mL (8.960 × 10-4 mol 1.5 equivalents) of triethylamine. 
3. Sonicate the above solution for about 10 min, and further stir under Argon until folic acid 
is totally dissolved (see Note 4). 
4. Add to the above homogeneous solution 0.13 g (11.295 × 10-4 mol, ~ 2 equivalents) of 
NHS and 0.235 g (11.38 × 10-4 mol, ~ 2 equivalents) of DCC. 
5. Keep the mixture under stirring overnight in dark at RT, to allow the formation of folic 
acid-NHS.  
6. Filter the resulting solution to remove the dicyclohexylurea byproduct (filtration is 
performed twice), and stock the final solution in dark at room T (see Note 5).  
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3.1.3 Synthesis of AuNP-PEI-FA 
1. Take 3 mL of AuNP-PEI and add 30 µL of 25 mg mL-1 folic acid-NHS in DMSO. Keep 
the AuNP-PEI, folic acid-NHS under stirring in dark at RT for 10 min. 
2. Add 50 µL of 0.1 M NaOH to the solution and leave it under stirring at RT for 48 h in 
dark, achieving AuNP-PEI-folic acid (thereafter referred as AuNP-PEI-FA).  
3. To purify the AuNP-PEI-FA solution centrifuge at 12,000 rpm for 5 min remove the 
supernatant containing unreacted folic acid-NHS 
4. The unreacted folic acid-NHS can be quantified by UV-vis (see Note 6). 
5. The size and zeta potential distribution were determined by DLS and Zeta potential 
measurements as shown in Fig 2 (see Note 7)   
3.2 Preparation of AuNP.siRNA complexes 
1. Solutions of 500 μg mL−1AuNP-PEI and 500 μg mL−1 AuNP-PEI-FA were added to 
0.264 μg μL−1 siRNA solutions at the mass ratio (MR) 20 of AuNPs to siRNA, followed 
by 1 h incubation with 400 rpm shaking at RT, in order to achieve the AuNP-PEI.siRNA 
and AuNP-PEI-FA.siRNA formulations.  
2. The ability of AuNPs to complex siRNA was analysed by gel retardation. Complexes of 
AuNPs and siRNA at different mass ratios (µg AuNPs to µg siRNA, siRNA was fixed to 
0.25 µg siRNA) were loaded onto 1% (w/v) agarose gels in 100 mL TBE buffer 
containing 6 μL SafeView.  
3. Electrophoresis was performed at 120 V for 30 min and the resulting gels were 
photographed under UV light (Fig. 3). 
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3.3 Cell culture 
1. LNCaP cells were maintained in RPMI-1640 medium supplemented with 10% FBS 
50 units mL−1 penicillin, 50 μg mL−1 streptomycin, 2 mM L-Glutamine, 10 mM HEPES, 
7.2 mM d-glucose and 1 mM Sodium Pyruvate. 
2. PC-3 cells were maintained in RPMI-1640 medium supplemented with 10% FBS.  
3. All cells were grown in the incubator at 37 °C with 5% CO2 and 95% relative humidity. 
3.4 Fluorescence activated cell sorting 
1. 100,000 LNCaP cells and 100,000 PC-3 cells were respectively seeded per well in 24-
well plates and incubated for 24 h under the growth conditions mentioned above.  
2. Cells were transfected with AuNP-PEI.siRNA (25 and 50 nM FAM siRNA) and AuNP-
PEI-FA.sRNA (25 and 50 nM FAM siRNA) and incubated for 24 h in the growth 
medium mentioned above.  
3. Following incubation cells were washed twice with PBS and trypsinised with Trypsin-
EDTA.  
4. Cells were subsequently centrifuged (1000 rpm for 5 min) and re-suspended in 1000 μL 
ice-cold PBS in Polystyrene Round-Bottom Tubes.  
5. Ten thousands cells per sample were measured following the procedure outlined in 
Becton Dickinson FACScalibur manual. Fluorescein-positive cells (%) were displayed by 
Dot Plot (Fig. 4). 
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3.5 Confocal microscopy 
1. 300,000 LNCaP cells were seeded per well in 6-well culture plates with glass bottom.. 
Cells were treated with the AuNP-PEI-FA formulation containing 50 nM FAM siRNA 
and incubated under the growth conditions (mentioned above) for 24 h.  
2. In order to label late endosomes and lysosomes, 75 nM LysoTracker® Deep Red were 
added to cells for 30 min at 37 °C.  
3. The medium was then replaced with fresh growth medium. The intracellular route was 
analyzed using the confocoal microscopy (Fig. 5). 
3.6 In vitro gene silencing 
1. 200,000 LNCaP cells were seeded per well in 12-well plates and incubated for 24 h under 
the growth conditions mentioned above.  
2. Cells were then transfected by the AuNP-PEI-FA formulation (MR20) containing 50 nM 
RelA siRNA for 24 h. 50 nM naked RelA siRNA and the AuNPs-PEI-FA formulation 
containing 50 nM Negative Control siRNA were used as the negative controls. 
3. Following incubation total RNA was isolated from the cells using the GenElute™ 
Mammalian Total RNA Miniprep Kit, according to the instructions supplied.  
4. First-strand cDNA was generated from total RNA samples using High-Capacity cDNA 
Reverse Transcription Kits.  
5. Gene expression was assessed by real-time quantitative PCR (qPCR) using the Applied 
Biosystems Real Time PCR System. Assays were performed using appropriate primers 
for RelA and GAPDH. Amplification was carried out by 40 cycles of denaturation at 
95 °C (15 s) and annealing at 60 °C (1 min). The quantitative level of each RelA mRNA 
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was measured as a fluorescent signal corrected according to the signal for GAPDH 
mRNA using 2-ΔΔ Ct method [13] (Fig 6). 
4. Notes  
1. Addition of PEI 2KD to 1 mM HAuCl4.3H2O form a complex between the AuCl4- ions 
and the amino groups in PEI detected by a change of colour from pale yellow to orange. 
To reduce the complex, immediately inject an excess of ~ 1.55 eq of Ascorbic Acid. The 
AuNPs formation can be easily observed by a colour change from yellow to red. Keep the 
stirring overnight to make sure that all gold is reduced and to stabilize the final AuNPs-
PEI size. 
2. Stirring a high concentration of 1 mM AuNPs overnight can cause some adsorption of the 
resulting AuNPs-PEI onto the wall of the round flask. Therefore, the adsorbed AuNPs 
might be recollected by sonication about 30 seconds.  
3. The obtained AuNPs-PEI can be characterised by UV-vis spectroscopy (Fig 1), the 
obtained AuNPs-PEI by the above mentioned method shows an absorption band at λmax 
560 nm at the origin of the red colloidal solution. This is the surface Plasmon resonance 
band characteristic of AuNPs colloidal solutions. Furthermore, SEM analysis (Fig 1) 
proves the formation of AuNPs with a diameter of ~110 nm as determined by Image J 
software.  
4. To dissolve the 0.25 g of Folic acid in DMSO, it was necessary to sonicate the solution 
for about 10 mins followed by stirring for another 30 min. Folic acid need to be 
manipulated in dark as it is light sensitive. 
5. The above mentioned synthesis of folic acid-NHS is known to yield approximately 80% 
 γ-carboxyl group of folic acid, preserving the binding of activated folate to folate 
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receptors [14]. The byproduct dicyclohexylurea is insoluble in water and is separated by 
simple filtration. The solution of 25 mg mL-1 folic acid-NHS in DMSO can be used 
without further purification. 
6. Folic acid activated with N-hydroxysuccinimide ester becomes ready to react with free 
amino group in PEI at a pH (7 to 8), to produce an amide linkage between the Folic Acid 
and AuNPs-PEI leading to AuNPs-PEI-FA. To purify the final AuNPs-PEI-FA solution 
centrifuge at 12,000 rpm for 5 min remove carefully the supernatant containing the 
unreacted folic acid-NHS and run a UV-vis spectrum to quantify the Folic acid attached 
to the AuNPs.  
7. To confirm the formation of AuNP-PEI-FA perform DLS/Zeta Potential analysis, the 
later show a very slight increase in the size distribution of AuNPs-PEI and a decrease in 
the value of the Zeta potential confirming the successful attachment of FA (Fig. 2). 
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List of Figures  
Fig. 1 UV-visible spectra of AuNPs-PEI (left) and SEM image (right) of AuNPs-PEI (bar = 5 
µm)  
 
Fig. 2 Size distribution by intensity (left) of AuNPs-PEI (113 ± 1 nm, PDI = 0.07, n = 3) and 
AuNPs-PEI-FA (118 ± 1 nm, PDI = 0.09, n = 3); insert show that the size is slightly increased; 
Zeta potentials (right) of AuNPs-PEI (53 ± 1 mV, n = 3) and AuNPs-PEI-FA (46± 1 mV, n = 3) 
as obtained from DLS analysis. (Reproduced with permission from the Elsevier Copyright 
Clearance Center; J. Guo et al. International Journal of Pharmaceutics 509 (2016) 16–27) 
 
Fig. 3 Complexation of siRNA (0.25 µg) with (A)AuNPs-PEI and (B) AuNPs-PEI-FA at 
different mass ratios (MRs) using gel retardation (1% agarose gel at 120 mV for 30 min). 
(Reproduced with permission from the Elsevier Copyright Clearance Center; J. Guo et al. 
International Journal of Pharmaceutics 509 (2016) 16–27) 
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Fig. 4 Fluorescein-positive PC-3 and LNCaP cells (%, mean ± SD) after 24 h transfection of 
AuNPs-PEI-FA.FAMsiRNA (MR20, 50 nM siRNA) analysed using flow cytometry (PC-3 = 
receptor negative cells and LNCaP cells = receptor positive cells). (**P < 0.01 and ***P < 0.001 
compared to the untreated control). (Reproduced with permission from the Elsevier Copyright 
Clearance Center; J. Guo et al. International Journal of Pharmaceutics 509 (2016) 16–27) 
 
Fig. 5 Arepresentative image showing intracellular distribution of AuNPs-PEI-FA formulation 
(MR20) containing FAM siRNA (50 nM) in LNCaP cells at 24 h post-transfection by confocal 
microscope. Late endosomes and lysosomes were labelled with 75 nMLysoTracker® Deep Red 
(Green = FAM siRNA, Red = LysoTracker® Deep Red). Most siRNAs were found in the 
cytoplasm. It is interesting to note that some FAM siRNAs were also found inside nucleus as 
indicated by arrows.  
 
Fig. 6 Endogenous gene silencing in LNCaP cells by RelA siRNA (50 nM) formulated with 
AuNPs-PEI-FA (MR20) at 24 h post transfection.The naked RelA siRNA (50 nM) and Negative 
Control siRNA (50 nM) formulated with AuNPs-PEI-FA (MR20) were used as controls 
(NS = no significance, *P < 0.05 compared to formulation containing Negative Control siRNA). 
(Mean ± SD, n = 3). (Reproduced with permission from the Elsevier Copyright Clearance 
Center; J. Guo et al. International Journal of Pharmaceutics 509 (2016) 16–27) 
 
 
 
